Recent Updates
Recently added Catalysts
DFTX Positive Sentiment

Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

Thursday, July 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Definium Therapeutics, a late-stage clinical biopharmaceutical company, will report its second quarter financial results for 2026 on August 6, 2026. The company aims to address psychiatric and neurological disorders with its therapeutics. A webcast will be held at 4:30 p.m. EDT to discuss these results and recent business highlights.
Price reaction · baseline $44.49 (2026-07-30 close) · hit after-hours · clean, no other DFTX news in the window
day 0 close · peak
-2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Definium Therapeutics is progressing in the late-stage clinical phase.
  • The company is focused on addressing significant psychiatric and neurological disorders.
  • The upcoming financial results may indicate positive growth and business highlights.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+130%
120-day peak, hindsight
Typical move
3.9%
average across 2 past catalysts
Cash runway
~59 mo
Minimal dilution risk
Lead asset
DT120
Phase 3 · Major Depressive Disorder

Full Press Release Details

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30 p.m. EDT on Thursday, August 6, 2026 to report financial results for the second quarter ended June 30, 2026, and discuss recent business highlights. Listeners can register for the webcast via this link.

Frequently Asked Questions

When will Definium Therapeutics report its Q2 2026 results?

Definium Therapeutics will report its Q2 2026 results on August 6, 2026.

What time is the webcast for the financial results?

The webcast will be held at 4:30 p.m. EDT.

What is the focus of Definium Therapeutics?

Definium Therapeutics develops therapeutics for psychiatric and neurological disorders.

How can I register for the webcast?

Listeners can register for the webcast via the provided link.

ShareAdd on Google
Tags: DFTX Definium Therapeutics financial results webcast psychiatric disorders
Last updated: Jul 30, 2026

Biotech snapshot

Cash runway
$1084M liquidity · $18M/mo burn
~59 mo
Minimal dilution risk
Lead asset
DT120Phase 3
Major Depressive Disorder →

Catalyst track record

+130%
best trade around DFTX's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DFTX.

See every catalyst's timing & PoA →